Cochrane · systematic review · CD003082
Haloperidol versus placebo for schizophrenia
Adams, CE, Bergman, H, Irving, CB, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 28.6%Very low 2 · 28.6%Low 0 · 0%Moderate 3 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
HALOPERIDOL versus PLACEBO for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death ‐ suicide and natural causes HALOPERIDOL vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |
Overall improvement: No marked global improvement Rated by clinician HALOPERIDOL vs PLACEBO | RR 0.67 [0.58, 0.78] | 8 studies · 307 participants | Moderate Downgraded: risk of bias, imprecision |
Not discharged from hospital HALOPERIDOL vs PLACEBO | RR 0.85 [0.47, 1.52] | 1 study · 33 participants | Very low Downgraded: risk of bias |
Relapse HALOPERIDOL vs PLACEBO | RR 0.69 [0.55, 0.86] | 2 studies · 70 participants | Very low Downgraded: risk of bias, imprecision |
Leaving the study early HALOPERIDOL vs PLACEBO | RR 0.54 [0.29, 1] | 8 studies · 304 participants | Moderate Downgraded: risk of bias, imprecision |
Satisfaction with treatment HALOPERIDOL vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: Movement disorders ‐ parkinsonism HALOPERIDOL vs PLACEBO | RR 5.48 [2.68, 11.22] | 5 studies · 485 participants | Moderate Downgraded: risk of bias, imprecision |